Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
Cannabidiol
Clobazam
Dravet syndrome
Drug-drug interaction
Epilepsy
Lennox-Gastaut syndrome
Seizures
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
18
05
2020
revised:
15
06
2020
accepted:
19
06
2020
pubmed:
28
6
2020
medline:
2
3
2021
entrez:
28
6
2020
Statut:
ppublish
Résumé
The efficacy of cannabidiol (CBD) with and without concomitant clobazam (CLB) was evaluated in stratified analyses of four large randomized controlled trials, two in Lennox-Gastaut syndrome, and two in Dravet syndrome. Each trial of CBD (Epidiolex The meta-analysis favored CBD vs. placebo regardless of CLB use. The treatment ratio (95% CI) of CBD over placebo for the average reduction in seizure frequency was 0.59 (0.52, 0.68; P < .0001) with CLB and 0.85 (0.73, 0.98; P = .0226) without CLB, and the 50% responder rate odds ratio (95% CI) was 2.51 (1.69, 3.71; P < .0001) with CLB and 2.40 (1.38, 4.16; P = .0020) without CLB. Adverse events (AEs) related to somnolence, rash, pneumonia, or aggression were more common in patients with concomitant CLB. There was a significant exposure/response relationship for CBD and its active metabolite. These results indicate CBD is efficacious with and without CLB, but do not exclude the possibility of a synergistic effect associated with the combination of agents. The safety and tolerability profile of CBD without CLB show a lower rate of certain AEs than with CLB.
Identifiants
pubmed: 32592183
doi: 10.1111/ane.13305
pmc: PMC7689899
doi:
Substances chimiques
Anticonvulsants
0
Cannabidiol
19GBJ60SN5
Clobazam
2MRO291B4U
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
531-540Subventions
Organisme : GW Research Ltd
Informations de copyright
© 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.
Références
Acta Neurol Scand. 2020 Dec;142(6):531-540
pubmed: 32592183
Lancet. 2005 Jan 8-14;365(9454):176-86
pubmed: 15639301
Lancet. 1999 Nov 27;354(9193):1896-900
pubmed: 10584742
Epilepsy Behav. 2017 May;70(Pt B):319-327
pubmed: 28190698
JAMA. 2016 Nov 1;316(17):1818-1819
pubmed: 27802529
N Engl J Med. 2018 May 17;378(20):1888-1897
pubmed: 29768152
N Engl J Med. 2017 May 25;376(21):2011-2020
pubmed: 28538134
Epilepsia. 2019 Nov;60(11):2224-2234
pubmed: 31625159
CNS Drugs. 2020 Mar;34(3):229-241
pubmed: 32040850
Epilepsia. 2017 Sep;58(9):1586-1592
pubmed: 28782097
Neurology. 2018 Apr 3;90(14):e1204-e1211
pubmed: 29540584
Epilepsy Behav. 2017 May;70(Pt B):313-318
pubmed: 28087250
Epilepsia. 2020 Jun;61(6):1082-1089
pubmed: 32452568
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
J Pharm Pharmacol. 1984 Sep;36(9):636-8
pubmed: 6149294
Hippokratia. 2010 Dec;14(Suppl 1):29-37
pubmed: 21487488
Lancet. 2018 Mar 17;391(10125):1085-1096
pubmed: 29395273
Ther Drug Monit. 2013 Feb;35(1):30-47
pubmed: 23318278
Epilepsia. 2020 Jun;61(6):1090-1098
pubmed: 32452532
Epilepsia. 2015 Aug;56(8):1246-51
pubmed: 26114620
Clin Pharmacol Drug Dev. 2019 Nov;8(8):1009-1031
pubmed: 30791225
Neurochem Res. 2017 Jul;42(7):1939-1948
pubmed: 28478594
JAMA Neurol. 2020 May 1;77(5):613-621
pubmed: 32119035